Richard Chin
In his new role, Chin will become the chairman of the compensation committee and a member of the audit committee.
He currently also serves on the adjunct faculty at the University of California (UCL), and is on the board at Genmedica Therapeutics.
ImmunoCellular chairman John Yu said: “Richard’s extensive experience in drug development will be valuable as the Company advances its Phase II clinical trial of ICT-107 (a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma)”.